2,318,543 Shares in Cencora, Inc. $COR Acquired by Norges Bank

Norges Bank purchased a new stake in Cencora, Inc. (NYSE:COR) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 2,318,543 shares of the company’s stock, valued at approximately $695,215,000.

A number of other large investors have also modified their holdings of COR. Voleon Capital Management LP acquired a new stake in Cencora in the first quarter valued at approximately $3,111,000. Baader Bank Aktiengesellschaft raised its holdings in shares of Cencora by 318.5% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after purchasing an additional 3,300 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after purchasing an additional 1,171 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after purchasing an additional 232,539 shares during the last quarter. Finally, Fiduciary Alliance LLC purchased a new position in Cencora in the second quarter valued at $262,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 46,640 shares of company stock worth $14,099,338. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of several recent analyst reports. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research note on Tuesday. TD Cowen lifted their price target on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Evercore ISI set a $400.00 price target on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Friday. Finally, UBS Group boosted their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Stock Up 0.1%

Shares of NYSE COR opened at $368.93 on Friday. The firm has a market cap of $71.53 billion, a P/E ratio of 37.96, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54. The firm’s 50 day moving average price is $335.71 and its 200 day moving average price is $307.44.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the firm posted $3.34 EPS. Cencora’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Cencora’s payout ratio is currently 30.19%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.